Trial Profile

An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use
Acronyms DISCOVER
Sponsors Regeneron Pharmaceuticals

Most Recent Events

07 Jun 2025 According to a Regeneron Pharmaceuticals Media Release, data from this study were shared in an oral presentation at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.
07 Jun 2025 Results published in the Regeneron Pharmaceuticals Media Release.
10 Dec 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com